

Clinical Trials Investigating New Agents for the Treatment of NCFBE



Phase 1

[Phase 1 BI 1323495 \(Neutrophil Elastase Inhibitor\)](#)

[Phase 1 CHF 6333 \(Neutrophil Elastase Inhibitor\)](#)

[Phase 1 Nebulized Human Plasma-Derived Polyvalent IgG](#)

Phase 2

[Phase 2 Willow Study \(Brensocaticib\)](#)

[Phase 2 HSK31858 \(DPP-1 inhibitor\)](#)

[Phase 2 Ascorbic Acid/Glutathione/Bicarbonate Inhalation](#)

Phase 3

[Phase 3 ASPEN Study \(Brensocaticib\)](#)

[ASPEN Expanded Access Study \(Brensocaticib\)](#)